{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2014-11-27&min-answer.dateOfAnswer=2014-12-04&hansardHeading=Pancreatic+Cancer%3A+Drugs", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?date=2014-11-27&min-answer.dateOfAnswer=2014-12-04&hansardHeading=Pancreatic+Cancer%3A+Drugs", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2014-11-27&min-answer.dateOfAnswer=2014-12-04&_metadata=all&hansardHeading=Pancreatic+Cancer%3A+Drugs", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2014-11-27&min-answer.dateOfAnswer=2014-12-04&_page=0&hansardHeading=Pancreatic+Cancer%3A+Drugs", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2014-11-27&min-answer.dateOfAnswer=2014-12-04&hansardHeading=Pancreatic+Cancer%3A+Drugs", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2014-11-27&min-answer.dateOfAnswer=2014-12-04&hansardHeading=Pancreatic+Cancer%3A+Drugs", "items" : [{"_about" : "http://data.parliament.uk/resources/166622", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/166622/answer", "answerText" : {"_value" : "
The Government is committed to ensuring that patients have access to effective treatments, including those for pancreatic cancer, on terms that represent value to the National Health Service and the taxpayer.<\/p>
<\/p>
<\/p>
<\/p>
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the NHS on the clinical and cost-effectiveness of health technologies.<\/p>
<\/p>
<\/p>
<\/p>
NICE has recommended gemcitabine as a treatment option for pancreatic cancer in technology appraisal guidance published in May 2001, subject to certain clinical criteria, and has been asked to appraise a number of other pancreatic cancer drugs. NHS commissioners are legally required to fund treatments recommended by NICE technology appraisal guidance.<\/p>
<\/p>
<\/em><\/p> <\/p> Where a pancreatic cancer drug is not routinely available on the NHS, patients may be able to access it through the Cancer Drugs Fund.<\/p> <\/p> <\/p> <\/p> <\/p> NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition. <\/p> <\/p> <\/p> Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned by NHS England. NHS England\u2019s pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.<\/p> <\/p> <\/p> <\/p> <\/p> We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-12-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-05T14:28:28.01Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pancreatic Cancer: Drugs"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government, in the light of the proposed re-evaluation of treatments on the Cancer Drugs Fund list, what assurances they can provide to patients with pancreatic cancer that the latest medicines will continue to be made available to them on the National Health Service.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"}
], "uin" : "HL3213"}
, {"_about" : "http://data.parliament.uk/resources/166623", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/166623/answer", "answerText" : {"_value" : " The Government is committed to ensuring that patients have access to effective treatments, including those for pancreatic cancer, on terms that represent value to the National Health Service and the taxpayer.<\/p> <\/p> <\/p> <\/p> The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the NHS on the clinical and cost-effectiveness of health technologies.<\/p> <\/p> <\/p> <\/p> NICE has recommended gemcitabine as a treatment option for pancreatic cancer in technology appraisal guidance published in May 2001, subject to certain clinical criteria, and has been asked to appraise a number of other pancreatic cancer drugs. NHS commissioners are legally required to fund treatments recommended by NICE technology appraisal guidance.<\/p> <\/p> <\/em><\/p> <\/p> Where a pancreatic cancer drug is not routinely available on the NHS, patients may be able to access it through the Cancer Drugs Fund.<\/p> <\/p> <\/p> <\/p> <\/p> NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition. <\/p> <\/p> <\/p> Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned by NHS England. NHS England\u2019s pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.<\/p> <\/p> <\/p> <\/p> <\/p> We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-12-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-05T14:29:26.66Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pancreatic Cancer: Drugs"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what action they are taking to ensure that all treatments for advanced pancreatic cancer shown to be effective are made available to patients on the National Health Service.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"}
], "uin" : "HL3214"}
, {"_about" : "http://data.parliament.uk/resources/166624", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/166624/answer", "answerText" : {"_value" : " We have had no such discussions. These are matters for NHS England\u2019s Cancer Drugs Fund clinical panel.<\/p> <\/p> <\/p> <\/p> <\/p> In making such decisions, the panel will take into account a number of factors, including unmet need.<\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-12-04", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "HL3216"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-04T16:06:53.823Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pancreatic Cancer: Drugs"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what discussions they have had with NHS England regarding unmet need in respect of pancreatic cancer treatment when re-evaluating medicines on the Cancer Drugs Fund list.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"}
], "uin" : "HL3215"}
, {"_about" : "http://data.parliament.uk/resources/166625", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/166625/answer", "answerText" : {"_value" : " We have had no such discussions. These are matters for NHS England\u2019s Cancer Drugs Fund clinical panel.<\/p> <\/p> <\/p> <\/p> <\/p> In making such decisions, the panel will take into account a number of factors, including unmet need.<\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-12-04", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "HL3215"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-04T16:06:53.887Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pancreatic Cancer: Drugs"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what discussions they have had with NHS England regarding innovation in pancreatic cancer treatment when assessing medicines for inclusion on the Cancer Drugs Fund list.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"}
], "uin" : "HL3216"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 4, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
NHS England\u2019s Cancer Drugs Fund panel plans to assess, on the basis of the latest evidence, whether certain drugs, including Abraxane (albumin bound paclitaxel) for advanced pancreatic cancer, should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.<\/p>
We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.<\/p>
NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK - one of which will be on pancreatic cancer - into the use of Stereotactic Ablative Radiotherapy (SABR), an innovative radiotherapy treatment. This will allow patients to receive SABR treatment where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of this treatment so that, if it proves to be effective, it will be available for patients on the NHS where appropriate.<\/p>
NHS England\u2019s Cancer Drugs Fund panel plans to assess, on the basis of the latest evidence, whether certain drugs, including Abraxane (albumin bound paclitaxel) for advanced pancreatic cancer, should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.<\/p>
We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.<\/p>
NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK - one of which will be on pancreatic cancer - into the use of Stereotactic Ablative Radiotherapy (SABR), an innovative radiotherapy treatment. This will allow patients to receive SABR treatment where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of this treatment so that, if it proves to be effective, it will be available for patients on the NHS where appropriate.<\/p>
The panel plans to meet on 15 and 16 December to assess, on the basis of the latest evidence, whether certain drugs should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.<\/p>
NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.<\/p>
The panel plans to meet on 15 and 16 December to assess, on the basis of the latest evidence, whether certain drugs should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.<\/p>
NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.<\/p>